Nanoscope Therapeutics Sanal Klinik Perspektifler Etkinliği

It is an online conference event held by Nanoscope Therapeutics on November 17, 2022. ***Activate the Subtitle from the options of the video player. In the settings icon, you can translate and watch Turkish from the automatic translation to the subtitle language. Nanoscope Therapeutics is developing optogenetic gene therapies that use Multi-Character Opsin (MCO) to resensitize the retina to detect low light levels. These treatments have the potential to restore vision in millions of visually impaired individuals suffering from retinal degenerative diseases, including Retinitis Pigmentosa, Stargardt's Disease, and Dry Age-Related Macular Degeneration (AMD). MCO-010 for RP and Stargardt Disease Our flagship product, MCO-010, is in clinical development for retinitis pigmentosa (RP) and Stargardt disease, two rare retinal diseases that cause blindness. MCO-010 has been given the title of Authorized Drug for both diseases by the US Food and Drug Administration. MCOs have the potential to address all forms of retinal degeneration and can be applied to patients suffering from complete or partial damage to the retina. Nanoscope's MCO-010 gene therapy uses a convenient and rooted intraocular injection to deliver a gene encoding the ambient light-sensitive MCO protein into retinal cells. The aim of these treatments is to enable retinal cells to perceive light so that patients with retinitis pigmentosa or Stargardt's disease can see again. How does our proprietary technology differ from other gene therapies? Our therapy focuses on treating blindness regardless of the underlying genetic mutation. It is an ambient light sensitive therapy in which a polychromatic Opsin is delivered to the retinal cells that enable vision in different color environments. Simple and convenient office-based procedure does not require invasive ocular surgery. No external device or stimulation is required, eliminating the risk of phototoxicity. Nano Enhanced Optical Transmission – NOD Imagine carrying new genetic material into retinal cells without any viruses. The company has strategic partnerships to create a unique non-viral alternative gene delivery platform designed to improve targeting precision with less immunogenicity. The non-viral technology includes near-infrared laser-based spatially targeted nano-enhanced delivery (NOD) of therapeutic genes. This technology can be used alongside optical gene therapies to provide genes competent to correct underlying genetic defects that lead to vision loss. Nanoscope Therapeutics, Inc. Trinity Towers 2777 N. Stemmons Fwy. Dallas, Texas 75207 (817) 857-1186 Source: Nanoscope Therapeutics Conference Website: https://nanostherapeutics.com #rp #retinitispigmentosa #retina #stargardt #optogenetic #genetics #eye #visualfield #sight